GSK's $10.6 Billion Nuvalent Deal Raises Eyebrows -- Market Talk

Dow Jones

Jun 09

0906 GMT - The initial market reaction to GSK's $10.6 billion acquisition of cancer specialist Nuvalent points to some trepidation among investors about the size of the deal, AJ Bell's Russ Mould says. Nuvalent is the U.K. drugmaker's biggest acquisition in years and fits with its goal of turning oncology into a key growth engine for the group, Mould says. "GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by [GSK CEO Luke] Miels in heralding the takeover still await regulatory approval," Mould says. "In rolling the dice on such a big transaction, he is undoubtedly taking a risk." GSK shares fall 3.3%. Nuvalent jumps 38% in U.S. premarket trading. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 09, 2026 05:07 ET (09:07 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2642465642"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642465642\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642465642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 17:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642465642","market":"other","top_or_hot":-1,"title":"GSK's $10.6 Billion Nuvalent Deal Raises Eyebrows -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0906 GMT - The initial market reaction to GSK's $10.6 billion acquisition of cancer specialist Nuvalent points to some trepidation among investors about the size of the deal, AJ Bell's Russ Mould says. Nuvalent is the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker's biggest acquisition in years and fits with its goal of turning oncology into a key growth engine for the group, Mould says. \"GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by [GSK CEO Luke] Miels in heralding the takeover still await regulatory approval,\" Mould says. \"In rolling the dice on such a big transaction, he is undoubtedly taking a risk.\" GSK shares fall 3.3%. Nuvalent jumps 38% in U.S. premarket trading. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 05:07 ET (09:07 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK's $10.6 Billion Nuvalent Deal Raises Eyebrows -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK's $10.6 Billion Nuvalent Deal Raises Eyebrows -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-09 17:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0906 GMT - The initial market reaction to GSK's $10.6 billion acquisition of cancer specialist Nuvalent points to some trepidation among investors about the size of the deal, AJ Bell's Russ Mould says. Nuvalent is the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker's biggest acquisition in years and fits with its goal of turning oncology into a key growth engine for the group, Mould says. \"GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by [GSK CEO Luke] Miels in heralding the takeover still await regulatory approval,\" Mould says. \"In rolling the dice on such a big transaction, he is undoubtedly taking a risk.\" GSK shares fall 3.3%. Nuvalent jumps 38% in U.S. premarket trading. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 05:07 ET (09:07 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVL","symbol_name":"Nuvalent, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642465642","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642465642","pubTimestamp":1780996020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0906 GMT - The initial market reaction to GSK's $10.6 billion acquisition of cancer specialist Nuvalent points to some trepidation among investors about the size of the deal, AJ Bell's Russ Mould says. Nuvalent is the U.K. drugmaker's biggest acquisition in years and fits with its goal of turning oncology into a key growth engine for the group, Mould says. \"GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by [GSK CEO Luke] Miels in heralding the takeover still await regulatory approval,\" Mould says. \"In rolling the dice on such a big transaction, he is undoubtedly taking a risk.\" GSK shares fall 3.3%. Nuvalent jumps 38% in U.S. premarket trading. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVL":"Nuvalent, Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","GSK":"葛兰素史克","GSK.UK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","GSKH":"GSK plc ADRhedged","BK4539":"次新股"},"translate_title":"葛兰素史克(GSK)106亿美元的Nuvalent交易引发关注——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":0.6,"NUVL":1.5,"GSK":1.5,"GSK.UK":0.6},"content_text":"0906 GMT - The initial market reaction to GSK's $10.6 billion acquisition of cancer specialist Nuvalent points to some trepidation among investors about the size of the deal, AJ Bell's Russ Mould says. Nuvalent is the U.K. drugmaker's biggest acquisition in years and fits with its goal of turning oncology into a key growth engine for the group, Mould says. \"GSK is paying a hefty premium to get the deal over the line and the two big lung cancer products flagged by [GSK CEO Luke] Miels in heralding the takeover still await regulatory approval,\" Mould says. \"In rolling the dice on such a big transaction, he is undoubtedly taking a risk.\" GSK shares fall 3.3%. Nuvalent jumps 38% in U.S. premarket trading. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 05:07 ET (09:07 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}